跳至主要内容
临床试验/NCT05598788
NCT05598788已完成不适用

Development of a Microsampling Approach for Personalized Monitoring of Kinase Inhibitor Targeted Therapies

Rennes University Hospital6 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2023年3月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
160
试验地点
6
主要终点
Comparison of venous blood vs VAMS concentrations

研究概览

简要总结

The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

详细描述

The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib.

Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients treated with one of the 9 drugs concerned by the study : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib
  • person who does not object to their participation in the research

排除标准

  • Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty

结局指标

主要结局

Comparison of venous blood vs VAMS concentrations

时间窗: 1 day

Comparison of drug concentrations measured from the venous blood samples with concentrations measured from VAMS

次要结局

未报告次要终点

研究者

发起方
Rennes University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Microsampling Approach for Monitoring of Kinase... | 临床试验